Biotech Company Develops from Laboratory and Clinical Studies

A new biotech company aims to improve the diagnosis of diabetes and cancer.

The startup company, which developed from diabetes and genomic research, will offer biomedical institutions and pharmaceutical industries, services and research reagents.

Providing a variety of high-throughput scientific services the new company, Jinfiniti Biosciences, LLC is housed in the Medical College of Georgia (MCG) Life Sciences Business Development Center (Augusta, GA, USA). It offers nucleic acid isolation, genomic analysis, antibody production, immunoassays, medicinal chemistry, toxicity evaluation for clinical laboratories, academic and pharmaceutic institutions, and forensics.

Biomarkers are also being developed that will enable the introduction of simple urine and/or blood tests for early disease detection, diagnosis, and monitoring of treatment outcomes. Additionally, the company is developing new drugs and companion biomarkers for personalized medicine.

Dr. Jin-Xiong She, director of the MCG Center for Biotechnology and Genomic Medicine and president and CEO of the new company, said, "There are many wonderful scientific discoveries but the vast majority never translates into medical practice." Dr. She wants to help scientists close that gap. "That is what startup companies are trying to do: take discoveries to the next step so that big companies become interested."

Jinfiniti Biosciences, LLC focuses on commercialization of technologies and discoveries developed by the company founder, Dr. Jin-Xiong She. He is an authority in the fields of high throughput technologies in genomics, proteomics, and biomarker and drug development.

Related Links:
Jinfiniti Biosciences, LLC
Medical College of Georgia Life Sciences Business Development Center